Jane A Buxton1, Jin Hee Kim. 1. BC Centre for Disease Control, University of British Columbia, Vancouver, British Columbia.
Abstract
UNLABELLED: In persons with chronic hepatitis C virus (HCV) infections, superinfection by hepatitis A virus (HAV) or hepatitis B virus (HBV) can cause serious complications, including fulminating hepatitis or increased severity of hepatitis. Therefore, it is important to adequately protect persons with chronic HCV infections by immunization. Suboptimal response to vaccines has been reported in patients with chronic liver disease. The present article reviews HAV and HBV vaccine responses reported in the literature when administered to individuals with chronic HCV infection, and reviews current national and international recommendations. RESULTS: Persons with chronic HCV respond well to HAV vaccine, but studies exploring HBV vaccine efficacy in this population have equivocal results. Vaccine schedules and participant characteristics differ among studies, and most do not adjust for confounders. Some studies found no difference in HBV vaccine response between patients with chronic HCV and controls. However, HBV vaccine response was generally reduced in those with cirrhosis and HCV genotype 1. Organizations recommend HAV and HBV vaccines for persons with chronic HCV, but do not suggest alterations in schedule or dose. RECOMMENDATIONS: Because HAV vaccine response is good and routine laboratory testing may not detect lower levels of vaccine-induced anti-HAV, the standard HAV vaccine schedule is recommended without postimmunization testing. HBV vaccine should be administered early in the course of chronic HCV infection because response may be lower in patients with cirrhosis. Reflex testing of anti-HCV reactive sera for anti-HAV and hepatitis B surface antibody can facilitate appropriate follow-up and timely immunization. Determination of postimmunization hepatitis B surface antibody, especially in patients with cirrhosis or genotype 1, will allow HBV vaccine boosters to be offered.
UNLABELLED: In persons with chronic hepatitis C virus (HCV) infections, superinfection by hepatitis A virus (HAV) or hepatitis B virus (HBV) can cause serious complications, including fulminating hepatitis or increased severity of hepatitis. Therefore, it is important to adequately protect persons with chronic HCV infections by immunization. Suboptimal response to vaccines has been reported in patients with chronic liver disease. The present article reviews HAV and HBV vaccine responses reported in the literature when administered to individuals with chronic HCV infection, and reviews current national and international recommendations. RESULTS:Persons with chronic HCV respond well to HAV vaccine, but studies exploring HBV vaccine efficacy in this population have equivocal results. Vaccine schedules and participant characteristics differ among studies, and most do not adjust for confounders. Some studies found no difference in HBV vaccine response between patients with chronic HCV and controls. However, HBV vaccine response was generally reduced in those with cirrhosis and HCV genotype 1. Organizations recommend HAV and HBV vaccines for persons with chronic HCV, but do not suggest alterations in schedule or dose. RECOMMENDATIONS: Because HAV vaccine response is good and routine laboratory testing may not detect lower levels of vaccine-induced anti-HAV, the standard HAV vaccine schedule is recommended without postimmunization testing. HBV vaccine should be administered early in the course of chronic HCV infection because response may be lower in patients with cirrhosis. Reflex testing of anti-HCV reactive sera for anti-HAV and hepatitis B surface antibody can facilitate appropriate follow-up and timely immunization. Determination of postimmunization hepatitis B surface antibody, especially in patients with cirrhosis or genotype 1, will allow HBV vaccine boosters to be offered.
Entities:
Keywords:
Hepatitis A virus; Hepatitis B virus; Hepatitis C virus; Immunization; Vaccine efficacy
Authors: D M Patrick; M W Tyndall; P G Cornelisse; K Li; C H Sherlock; M L Rekart; S A Strathdee; S L Currie; M T Schechter; M V O'Shaughnessy Journal: CMAJ Date: 2001-10-02 Impact factor: 8.262
Authors: Ramazan Idilman; Maria Nicola De; Alessandra Colantoni; Abdul Nadir; David H Van Thiel Journal: Am J Gastroenterol Date: 2002-02 Impact factor: 10.864
Authors: Morris Sherman; Vincent Bain; Jean-Pierre Villeneuve; Robert P Myers; Curtis Cooper; Steven Martin; Catherine Lowe Journal: Can J Infect Dis Med Microbiol Date: 2004-11 Impact factor: 2.471
Authors: David C Perlman; Ashly E Jordan; Courtney McKnight; Christopher Young; Kevin L Delucchi; James L Sorensen; Don C Des Jarlais; Carmen L Masson Journal: J Addict Dis Date: 2014
Authors: Noele P Nelson; Mark K Weng; Megan G Hofmeister; Kelly L Moore; Mona Doshani; Saleem Kamili; Alaya Koneru; Penina Haber; Liesl Hagan; José R Romero; Sarah Schillie; Aaron M Harris Journal: MMWR Recomm Rep Date: 2020-07-03
Authors: Carey L Shive; Chelsey J Judge; Brian Clagett; Robert C Kalayjian; Melissa Osborn; Kenneth E Sherman; Carl Fichtenbaum; Rajesh T Gandhi; Minhee Kang; Daniel L Popkin; Scott F Sieg; Michael M Lederman; Benigno Rodriguez; Donald D Anthony Journal: Vaccine Date: 2017-12-16 Impact factor: 4.169
Authors: Fabio Lugoboni; Raimondo Maria Pavarin; Chiara Resentera; Daniele Gambini Journal: Int J Environ Res Public Health Date: 2015-04-13 Impact factor: 3.390
Authors: Christabel Kelly; Leo Swadling; Stefania Capone; Anthony Brown; Rachel Richardson; John Halliday; Annette von Delft; Ye Oo; David Mutimer; Ayako Kurioka; Felicity Hartnell; Jane Collier; Virginia Ammendola; Mariarosaria Del Sorbo; Fabiana Grazioli; Maria Luisa Esposito; Stefania Di Marco; Loredana Siani; Cinzia Traboni; Adrian V S Hill; Stefano Colloca; Alfredo Nicosia; Riccardo Cortese; Antonella Folgori; Paul Klenerman; Eleanor Barnes Journal: Hepatology Date: 2016-01-22 Impact factor: 17.425